Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 1;9(9):e19604. doi: 10.1016/j.heliyon.2023.e19604

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 1 — Ophthalmological follow-up, noteworthy findings. (A, arrow) Ring protruding into the anterior chamber in the ventral region (Day 7; Rabbit 8, Control). (B, arrow) Decentered IOL (Day 7; Rabbit 12, Control). (C) Considerable increase in intraocular pressure causing dehiscence of the corneal suture, conjunctival congestion, and corneal cloudiness (Day 15; Rabbit 1, Study). (D) Iris's deformity compatible with posterior synechiae (Day 30; Rabbit 8, Control). (E) IOL in the anterior chamber and mucous secretion (Day 45; Rabbit 4, Control). (F) Buphthalmia and a soft oval-shaped mass in the sclero-conjunctival region prevent complete palpebral occlusion (Day 45; Rabbit 8, Control). (G) Corneal opacity (Day 90; Rabbit 15, Control). (H) Mild conjunctivitis and marked iris deformation (Day 120; Rabbit 1, Study). (I) Yellowish residue on the IOL (Day 150; Rabbit 12, Control). Study: Accommodative LUZ IOL; Control: EyeCee® IOL.